InMed Pharmaceuticals Inc (IN.TO)

Name: InMed Pharmaceuticals Inc Financial Statements
Creator: Quarter Results

Healthcare | Biotechnology

Latest reporting period: 2025-12-31

Latest Quarter

2025-12-31

Revenue

$1.1M

Net Income

-$2.8M

Operating Margin

-258.6%

Free Cash Flow

-$7.8M

Debt / Assets

13.8%

Values are in USD and rounded to the nearest whole number unless noted.

Swipe horizontally to view all columns.

Income statement quarterly history for InMed Pharmaceuticals Inc (IN.TO).
Income Statement (Quarterly)	2025-12-31	2025-09-30	2025-03-31	2024-12-31
Revenue	1,125,404	1,120,121	1,261,578,000	1,111,707,000
Cost of Revenue	1,089,489	716,962	1,085,953,000	650,813,000
Gross Profit	35,915	403,159	175,625,000	460,894,000
Operating Expenses
R&D Expenses	0	0	0	0
SG&A Expenses	2,080,529	1,532,015	1,328,996,000	1,553,583,000
Operating Expenses	2,945,843	2,166,829	2,238,649,000	2,613,950,000
Operating Income	-2,909,928	-1,763,670	-2,063,024,000	-2,153,056,000
Interest Expense	0	0	0	0
Income Before Tax	-2,782,985	-1,726,899	-2,120,930,000	-2,575,024,000
Income Tax Expense	0	0	0	0
Net Income	-2,782,985	-1,726,899	-2,120,930,000	-2,575,024,000
Per Share
EPS	-703.84	-436.75	-1.94	-3.64
EPS Diluted	0.00	0.00	0.00	0.00

Income statement annual history for InMed Pharmaceuticals Inc (IN.TO).
Income Statement (Annual)	2025-06-30	2024-06-30	2023-06-30	2021-06-30	2020-06-30
Revenue	4,942,633	4,597,730	4,135,561	0	0
Cost of Revenue	3,236,047	3,496,817	2,732,525	0	0
Gross Profit	1,706,586	1,100,913	1,403,036	0	0
Operating Expenses
R&D Expenses	0	0	0	0	0
SG&A Expenses	6,557,822	5,250,715	5,847,518	4,479,333	3,978,829
Operating Expenses	9,624,581	9,015,743,000	9,781,823	9,938,283	8,867,885
Operating Income	-7,917,995	0	-8,176,538,000	-9,938,283	-8,867,885
Interest Expense	373,105	0	0	360,350	18,616
Income Before Tax	-8,162,133	-7,668,450	-7,934,522	-10,203,089	-8,681,266
Income Tax Expense	0	7,100	13,100	0	0
Net Income	-8,162,133	-7,675,550	-7,947,622	-10,203,089	-8,681,266
Per Share
EPS	-11.44	-1.01	-4.30	-1.95	-1.66
EPS Diluted	0.00	0.00	0.00	0.00	0.00

Balance sheet quarterly history for InMed Pharmaceuticals Inc (IN.TO).
Balance Sheet (Quarterly)	2025-06-30	2024-06-30	2021-06-30	2020-06-30
Assets
Cash and Cash Equivalents	15,090,098	8,987,530	7,363,126	5,793,056
Short Term Investments	0	0	46,462	42,291
Net Receivables	633,671	482,551	11,919	45,244
Inventory	1,309,530	1,701,774	0	0
Total Current Assets	17,530,766	11,884,137	8,378,269	6,298,591
Property Plant Equipment	1,351,801	1,709,536	326,595	402,598
Goodwill and Intangibles	2,207,902	2,438,755	1,061,697	799,269
Total Assets	21,226,713	16,169,191	9,781,216	7,500,459
Liabilities
Account Payables	504,292	856,396	775,129	0
Short Term Debt	593,348	434,628	80,483	68,814
Total Current Liabilities	2,506,585	2,696,703	2,215,361	1,672,586
Long Term Debt	416,569	881,936	189,288	247,466
Total Liabilities	2,923,154	3,578,640	2,404,649	1,920,052
Shareholders Equity
Retained Earnings	-159,728,421	-149,175,280	-74,852,470	-55,957,671
Total Shareholders Equity	18,303,559	12,590,550	7,376,567	5,580,407

Balance sheet annual history for InMed Pharmaceuticals Inc (IN.TO).
Balance Sheet (Annual)	2025-06-30	2024-06-30	2021-06-30	2020-06-30	2019-06-30
Assets
Cash and Cash Equivalents	15,090,098	8,987,530	7,363,126	5,793,056	9,806,491
Short Term Investments	0	0	46,462	42,291	3,934,410
Net Receivables	633,671	482,551	11,919	45,244	64,737
Inventory	1,309,530	1,701,774	0	0	0
Total Current Assets	17,530,766	11,884,137	8,378,269	6,298,591	14,128,821
Property Plant Equipment	1,351,801	1,709,536	326,595	402,598	42,527
Goodwill and Intangibles	2,207,902	2,438,755	1,061,697	799,269	902,438
Total Assets	21,226,713	16,169,191	9,781,216	7,500,459	15,073,785
Liabilities
Account Payables	504,292	856,396	775,129	0	1,190,482
Short Term Debt	593,348	434,628	80,483	68,814	0
Total Current Liabilities	2,506,585	2,696,703	2,215,361	1,672,586	1,190,482
Long Term Debt	416,569	881,936	189,288	247,466	0
Total Liabilities	2,923,154	3,578,640	2,404,649	1,920,052	1,190,482
Shareholders Equity
Retained Earnings	-159,728,421	-149,175,280	-74,852,470	-55,957,671	-49,185,035
Total Shareholders Equity	18,303,559	12,590,550	7,376,567	5,580,407	13,883,303

Cash flow quarterly history for InMed Pharmaceuticals Inc (IN.TO).
Cash Flow Statement (Quarterly)	2025-06-30	2024-06-30	2021-06-30	2020-06-30
Operating Activities
Net Income	-8,162,133	-7,675,550	-10,203,089	-8,681,266
Depreciation & Amortization	534,725	604,518	120,866	221,218
Stock Based Compensation	119,307	137,714	610,193	1,252,593
Change in Working Capital	-337,167	-369,338	-450,450	351,301
Operating Cash Flow	-7,766,951	-6,985,832	-9,790,640	-9,767,400
Investing Activities
Capital Expenditure	0	-9,293	-1,725	-57,163
Investments	0	0	-1,725	-41,853
Investing Cash Flow	0	-9,293	-1,725	3,619,537
Financing Activities
Debt Repayment	0	0	0	-97,375
Common Stock Issued/Repurchased	8,130,299	4,654,043	12,472,500	0
Dividends Paid	0	0	0	0
Financing Cash Flow	12,271,212	4,654,218	10,854,722	-101,016
Summary
Free Cash Flow	-7,766,951	-6,995,125	-9,792,365	-9,824,563
Net Change in Cash	4,504,261	-2,340,907	1,557,317	-4,961,805

Cash flow annual history for InMed Pharmaceuticals Inc (IN.TO).
Cash Flow Statement (Annual)	2025-06-30	2024-06-30	2021-06-30	2020-06-30	2019-06-30
Operating Activities
Net Income	-8,162,133	-7,675,550	-10,203,089	-8,681,266	-10,096,772
Depreciation & Amortization	534,725	604,518	120,866	221,218	124,344
Stock Based Compensation	119,307	137,714	610,193	1,252,593	4,083,157
Change in Working Capital	-337,167	-369,338	-450,450	351,301	283,892
Operating Cash Flow	-7,766,951	-6,985,832	-9,790,640	-9,767,400	-8,768,573
Investing Activities
Capital Expenditure	0	-9,293	-1,725	-57,163	-35,491
Investments	0	0	-1,725	-41,853	-27,035
Investing Cash Flow	0	-9,293	-1,725	3,619,537	-2,105,609
Financing Activities
Debt Repayment	0	0	0	-97,375	0
Common Stock Issued/Repurchased	8,130,299	4,654,043	12,472,500	0	272,500
Dividends Paid	0	0	0	0	0
Financing Cash Flow	12,271,212	4,654,218	10,854,722	-101,016	207,572
Summary
Free Cash Flow	-7,766,951	-6,995,125	-9,792,365	-9,824,563	-8,804,064
Net Change in Cash	4,504,261	-2,340,907	1,557,317	-4,961,805	-11,260,316